| abstract |
A recombinant chimeric adenovirus having a genome comprising an E2B region, wherein said E2B region comprises a nucleic acid sequence derived from a first adenoviral serotype and a nucleic acid sequence derived from a second adenovirus serotype; wherein said first and second adenoviral serotypes each of the adenoviral subgroups B, C, D, E, or F are selected and are different from each other; and wherein said chimeric adenovirus is oncolytic and demonstrates an improved therapeutic index for a tumor cell. |